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Abstract 
Aim: During diabetic pregnancy, complex metabolic changes occur in the lipid profile. The aim of 
the study was to determine the predictive values of maternal serum lipid levels on large-for-gesta-
tional age newborns during the third trimester in pregnancies of women with type 2 diabetes mellitus 
(DM2) and gestational diabetes mellitus (GDM). 
Material and methods: Data of forty three pregnancies of women with DM2 and two hundred 
women with GDM were analyzed. The analysis encompassed the following parameters: age, body 
mass index (BMI), lipid parameters, HbA1c in first, second and third trimester of pregnancy, 
preeclampsia and baby birth weight. 
Results: DM2 and GDM groups showed statistically significant differences in the following 
variables: total lipids, triglycerides, total cholesterol, BMI, age, baby birth weight, incidence of SGA 
and preterm delivery (9.4 ± 2.3 vs. 11.0 ± 2.3 mmol/L, 2.4 ± 1.4 vs. 3.4 ± 1.6 mmol/L, 5.5 ± 1.2 vs. 
6.4 ± 1.4 mmol/L, 30.6 ± 5.4 vs. 26.9 ± 5.2 kg/m2, 34 ± 7.8 vs. 31.5 ± 5.6 years, 3183 ± 972 vs. 3533 
± 699 g., 20% vs. 7.5%, 27.9 vs. 14%, respectively, p < 0.05). Linear multiple regression analysis 
demonstrated that triglycerides, LDL-C and total cholesterol were independent predictors of LGA (p 
< 0.05). 
Conclusion: Triglycerides and LDL-C in the third trimester of pregnancy are independent predictors 
for fetal macrosomia in DM2 and GDM pregnancies. Thus, the maternal serum triglycerides and 
LDL-C levels determined in the maternal blood taken in the third trimester of pregnancy may 
indentify women who will give birth to LGA newborns. 
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1. Introduction  
Macrosomia still complicates a signify-
cant proportion of diabetic pregnancies. Studies 
show that variations in birth weight which occur 
more often in diabetic pregnancies are not de-
termined only by the maternal glycemic state, 
but other metabolic factors as well, such as 
lipids, may have important influence [1–4]. 
Maternal lipid metabolism is altered du-
ring normal and diabetic pregnancy with incre-
ased insulin resistance combined with incre-
ased peripheral adipose tissue lipolysis. It re-
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sults in increased maternal lipoprotein con-
centrations [5, 6]. The abnormal lipid metabo-
lism has been associated with preterm delivery, 
preeclampsia and macrosomia. Furthermore, 
Freinkel et al. [7] proposed that “mixture” of 
maternal nutrients (glucose, amino acids and 
lipids) changes the metabolic environment of 
the fetuses and these changes not only that 
affect the fetal growth and development but also 
influence future obesity, diabetes and neuro-
cognitive development in the offspring (“fuel 
mediated-teratogenesis”). Lipids treatment is 
the key therapeutic target in non-pregnant dia-
betic settings. There are no recommendations 
for clinic management of lipids in pregnancy 
complicated by diabetes. Studies show lipid 
changes in the first, second and third trimester 
both in normal [8] as well as in diabetic 
pregnancies [9]. There is an association bet-
ween insulin resistance and serum lipid levels 
in pregnancy, as adaptive mechanism allowing 
fetal grown. Serum lipids are higher in obesity, 
gestational diabetes mellitus (GDM), type 1 
diabetes mellitus (DM1), and type 2 diabetes 
mellitus (DM2). More, but not all studies have 
reported the same lipid profiles in well-
controlled DM1 as in normal pregnancies, high 
triglyceride and low HDL-C are found in DM1 
women with metabolic syndrome in pregnancy, 
and those diabetic women who develop pre-
eclampsia have high LDL-C and cholesterol 
levels. In pregnant GDM women frequent foun-
ding are the elevated triglycerides while in 
DM2 pregnancies the lipid profiles are between 
those observed in DM1 and GDM [9, 10]. Hence, 
we decided to explore lipids in DM2 and GDM 
pregnancies because the latter is a form of type 
2 diabetes and they share the same underlying 
pathophysiology (insulin resistance and beta 
cell dysfunction). 
The aim of the present study was to 
determine the contribution of maternal lipids in 
predicting (large-for-gestational age) macro-
somic newborns in pregnant women with DM2 
and GDM, with emphasis on the intergroup 
differences and development of macrosomia. 
 
2. Material and methods 
2.1. Study subjects 
The study was conducted at the Univer-
sity Clinic of Endocrinology, Diabetes and Me-
tabolic Disorders. Data of 43 pregnant women 
with DM2 and 200 women with GDM were 
analyzed. All were with singleton pregnancies, 
and neonates were delivered at the University 
Clinic of Gynecology and Obstetrics. The diag-
nosis of DM2 was made when patients have 
been treated with oral lowering medication 
before conception, were switched to insulin be-
fore or at early pregnancy, and without eviden-
ce of ketoacidosis. GDM was generally diag-
nosed by OGTT in the second part of preg-
nancy. The OGTT was performed in the mor-
ning after an overnight fasting from 8 to 12 h. 
The criteria for diagnosis of GDM were at least 
one abnormally high out of three plasma glu-
cose value measurements during the 75 g OGTT 
(normal values: a fasting level < 5.1, 1-hour 
level < 10.0, 2-hour level < 8.5 mmol/l). The 
venous blood glucose levels were measured 
using the glucose oxydase method (Glucose 
Analyzer; Beckman, Brea, CA). The glucose 
tolerance was classified by the latest criteria of 
the International Association of Diabetes in 
Pregnancy Study Group (IADPSG) [11]. 
All patients gave informed consent to 
participate in the study after a careful explana-
tion of the testing protocol. The study was 
made in accordance with the Declaration of 
Helsinki. 
2.2. Measurements 
The analyzed outcome measures were: 
age, BMI, lipid parameters in the third tri-
mester, HbA1c in the first, second and third 
trimester of the pregnancy, preeclampsia, and 
baby birth weight. The maternal glycemic pa-
rameters included glycosylated hemoglobin 
(HbA1c) in all three trimesters. HbA1c was 
measured with an ionexchange HPLC instru-
ment (DS5; Drew, USA) with a reference range 
of 4.2–6%. In the third trimester the fasting 
maternal total cholesterol, triglycerides, high-
density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C) were 
measured in both groups. The lipids assessment 
was taken after the overnight fasting. The 
blood samples for lipoproteins were analyzed 
using Cobas Integra 700, according to the stan-
dard methods. Total cholesterol and triglyceri-
des were determined with the full enzymatic 
methods (TCH-CHOD-POD-PAP and triglyceri-
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des-GPO; Cobas Integra 700, Hoffmann-La Ro-
che, Basel, Switzerland). The high density lipo-
protein cholesterol (HDL-C) was measured using 
the polyanion precipitation method, while LDL-
C was calculated using the Friedewald formula. 
The low density lipoprotein cholesterol (LDL-
C) was fractioned using ultracentrifugation in 
the cases of triglycerides exceeding 4mmol/l. 
The body mass index (BMI) of women with 
type 2 diabetes and GDM was calculated by 
dividing the weight with the height squared 
(kilograms/metar2). The BMI of 26 kg/m2 was 
defined as overweight and 30 kg/m2 as obesity. 
The baby birth weight was measured im-
mediately after delivery. The macrosomia was 
defined as birth weight greater than 4000 g; the 
large for gestational age (LGA) was defined as 
weight greater than the 90th percentile for 
gestational age and sex. The small for gesta-
tional age (SGA) was defined as birth weight 
lower than 2700 g. or the 10th percentile for 
gestational age and sex. The gestational age 
was estimated from the date of the last men-
strual period. The pre-term delivery was the 
birth before 37 weeks of pregnancy. 
The patients with DM2 were treated only 
with insulin. The patients with GDM were 
treated with diet, metformin or insulin accor-
ding to glycemic profiles. 
2.3. Statistical analyses 
The statistical analysis was performed 
using Statistics 7.0 version for Windows. The 
normal distribution of all variables was verified 
using Kolmogorov-Smirnov test. The data were 
presented as mean values, median and percen-
tage. The comparisons between the two groups 
were determined with the t-test for independent 
samples. The differences in proportions were 
compared with the Chi-square test. The correla-
tions were determined by the Pearson correla-
tion test. To estimate the independent effect of 
analyzed variables on LGA, linear multiple 
regression analysis was done. P < 0.05 was 
considered to be statistically significant.  
 
3. Results 
The study group consisted of 43 women 
with DM2 and 200 with GDM. The maternal 
characteristics of the diabetic pregnancies are 
listed in Table 1. The investigated groups were 
statistically different in the following variables: 
total lipids, triglycerides, total cholesterol, BMI, 
age, baby birth weight, and incidence of SGA 
(Table 1). 
 
Table 1 
 
The comparison of analyzed variables between the groups (DM2 and GDM) 
 
 
 DM2 GDM p value 
Total lipids (mmol/L) 9.4 ± 2.3 11.0 ± 2.3 < 0.01 
Triglycerides (mmol/L) 2.4 ± 1.4 3.4 ± 1.6 < 0.01 
Total cholesterol (mmol/L) 5.5 ± 1.2 6.4 ± 1.4 < 0.01 
HDL-C (mmol/L) 1.4 ± 0.3 1.5 ± 0.4 NS 
LDL-C (mmol/L) 3.1 ± 1.0 3.5 ± 1.2 NS 
HbA1c I trimester (%) 6.6 ± 1.5 7.1 ± 2.2 NS 
HbA1c II trimester (%) 5.9 ± 1.1 5.8 ± 0.9 NS 
HbA1c III trimester (%) 5.8 ± 1.0 5.8 ± 1.0 NS 
BMI kg/m2 30.6 ± 5.4 26.9 ± 5.2 < 0.05 
Age (years) 34 ± 7.8 31.5 ± 5.6 < 0.05 
Baby weight (g.) 3183 ± 972 3533 ± 699 < 0.05 
Preeclampsia 5/42 (11.9%) 8/155 (5.2%) NS 
LGA 9/35 (25.7%) 44/187 (23.5%) NS 
SGA 7/35(20%) 14/187 (7.5%) < 0.05 
g.w. of delivery (median) 37.5 39 NS 
preterm delivery 12/43 (27.9%) 28/200 (14%) < 0.05 
All data are presented as mean±SD, median and percentages; DM2: type 2 diabetes mellitus; GDM: gestational diabetes mellitus; 
HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; HbA1c: glycosylated hemoglobin; BMI: 
body mass index; LGA: large for gestational age; SGA: small for gestational age; g.w.: gestational week; NS: not significant. 
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The mean age of patients with DM2 and 
GDM were 34 ± 7.8 and 31 ± 5 years, respecti-
vely, showing statistically significant differen-
ce (p<0.05). The patients with DM2 were 
heavier (mean BMI 30.6 ± 5.6 kg/m2) in com-
parison to the GDM patients (mean BMI 26.9 ± 
5.2 kg/m2) and the difference was statistically 
significant (p < 0.05). 
 3.1. Glycemic control  
The maternal HbA1c values were similar 
in the DM2 patients and the GDM patients; 
there was no difference between the groups du-
ring the first, second and third trimester (Table 
1), yet all values indicated generally acceptable 
glycemic control. 
3.2. Lipids 
The plasma total lipids were lower in the 
DM2 (mean 9.4 ± 2.3 mmol/L) in comparison 
to the GDM patients (mean 11.0 ± 2.3 mmol/L), 
this difference was significant (p < 0.01). Stati-
stically significant differences were found bet-
ween the GDM patients and the DM2 patients 
in the mean plasma triglycerides concentrations 
(3.4 ± 1.6 and 2.4 ± 1.4 mmol/L, respectively), 
and the mean total cholesterol concentrations 
(6.4 ± 1.4 and 5.5 ± 1.2 mmol/L), (p < 0.01), 
whereas HDL-C and LDL-C concentrations were 
similar in both groups, using the National Edu-
cation Program criteria in the non-pregnant state. 
3.3. Neonate size  
The pregnancy outcomes are shown in 
Table1. The babies who were born by mothers  
 
Table 2 
 
with GDM had a mean birth weight of 3533 ± 
699g, they were heavier than those of mothers 
with DM2 (3183 ± 972g) and the statistical 
analyses showed significant differences between 
the two groups (p < 0.05) (Table 1.) The rate of 
macrosomia was comparable between two gro-
ups: 25.7% and 23.5% in DM2 and GDM 
groups, respectively. 
3.4. Interrelationships between meta-
bolic control, lipids and neonatal size 
(macrososmia /large-for-gestation age) 
Triglycerides concentrations were directly 
related to the HbA1c levels (r = 0.18, p < 0.05) 
and the HDL-C concentrations were associated 
with the values of HbA1c (r = 0.19, p < 0.05). 
The HDL-C concentrations were related to the 
newborn size, i.e. large-for-gestation age new-
borns (r = 0.17, p < 0.05). The HbA1c levels 
were associated with the small-for-gestation 
age newborns (r = 0.29, p < 0.05). The BMI 
was related with the LGA (r = 0.173, p < 0,01), 
preeclampsia (r = 0.228, p < 0,01), triglycerides 
(r = 0.137, p < 0,05), and age (r = 0.202, p < 0,01). 
The linear multiple regression analysis 
demonstrated that, triglycerides, LDL-C and 
total cholesterol concentrations were indepen-
dent predictors of LGA (p < 0.05) (Table 2). 
There were no independent relationships 
with the HDL-cholesterol concentrations and 
the HbA1c levels with the LGA. Surprisingly, 
the BMI was not independent predictor for 
LGA, as well as preeclampsia. 
 
Multivariate analyses of maternal LDL-C, triglycerides, and total cholesterol in the third trimester 
 as independent predictors of neonate size (LGA) 
 
Unstandardized Coefficients Standardized Coefficients  
B Std. Error Beta 
t value p value 
(Constant) -0.072 1.019  -0.071 0.944 
Triglycerides 0.253 0.119 0.608 2.133 0.043 
Total cholesterol -0.428 0.186 -1.161 -2.298 0.031 
HDL-C 0.047 0.299 0.033 0.156 0.877 
LDL-C 0.538 0.215 1.184 2.509 0.019 
BMI 0.007 0.019 0.068 0.348 0.731 
Hba1c I trimester -0.073 0.059 -0.278 -1.238 0.228 
Hba1c II trimester 0.118 0.156 0.200 0.754 0.458 
Hba1c III trimester 0.007 0.137 0.013 0.053 0.958 
Preeclampsia -0.260 0.253 -0.197 -1.027 0.315 
 
Dependent Variable: LGA; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; 
BMI: body mass index; HbA1c: glycosylated hemoglobin. 
 
 4. Discussion 
In this retrospective study on pregnant 
women with DM2 and GDM, we found mater-
nal triglyceride and cholesterol values in the 
third trimester of gestation to be important pre-
dictors for macrosomia, independent of the ma-
ternal pregnancy BMI and HbA1c values.  
Macrosomia occurs in 30–56% of the 
pregnancies complicated by DM2 and 10–20% 
of the pregnancies complicated by GDM, accor-
ding to the data from the literature. In this 
study, the frequency of macrosomia was simi-
lar in the DM2 and the GDM patients partly 
due to “good” glycemic control. HbA1c values 
were better than those found in the literature 
which emphasizes that in the glycemic control 
“almost good is not good enough”. Further, in a 
recent study we found no correlation between 
HbA1c and fetal macrosomia. It means that 
HbA1c is not a sensitive marker for prediction 
of macrosomia, or that the strict glycemic con-
trol can fail to prevent macrosomia. The fin-
dings in our study showed that fetal growth, 
behind maternal glucose concentration is influ-
enced also, by lipids. Many studies [12, 13] ob-
served that maternal serum lipids are associated 
with baby birth weight, independent of ma-
ternal weight gain and glucose.  
The normal pregnancy is a hyperlipide-
mic state mainly influenced by increments of 
estrogen [8]. The rising levels of estrogen with 
the progression of pregnancy reflects the chan-
ges in lipoproteins [9]. On the other hand, dys-
lipidemia increases with the insulin resistance 
found in obesity, GDM and preexisting diabe-
tes, as it has been extensively researched in the 
studies of Kitajima et al. [10], Knopp et al. [14] 
and Gobi et al. [15]. Hyperlipidemia in diabetes 
might also affect the fetal growth. In this paper 
we focused on lipids in the third trimester in 
pregnant women with DM2 and GDM. Key 
points were macrosomia and preeclampsia. We 
found higher levels of total cholesterol (6.4 ± 
1.4 mmol/l) in the GDM patients in comparison 
to the levels (5.5 ± 1.2 mmol/L) of the DM2 
patients. Further, the multivariate analysis sho-
wed the positive correlation between the mater-
nal cholesterol levels and the neonatal birth 
weight. Actually, the maternal cholesterol levels 
were independent predictor for macrosomia. 
This is in line with Schaefer et al. [16] who ob-
served a positive correlation between the ma-
ternal cholesterol levels in the third trimester 
and the neonatal birth weight. Some studies 
have reported that lipids play an important role 
in baby weigh as compared to glucose [12, 13].  
The most consistent lipid change in all 
studies is the level of triglycerides which shows 
progressive rise from the first, through the se-
cond, and to the third trimester [15]. The in-
crease in the lipid metabolism is an adaptation 
of the increased fuel delivery to the fetus. When 
they are too high, macrosomic babies are more 
likely to be born. Mothers with GDM had higher 
triglycerides levels (3.4 ± 1.6 mmol/L) in com-
parison to the triglyceride levels in the DM2 
patients (2.4 ± 1.4 mmol/L) (p < 0.01). In this 
study, the triglycerides in the third trimester 
were the strongest predictor of macrosomia. The 
increased triglycerides during the late preg-
nancy are due to the increased hepatic produc-
tion of VLDL under the stimulation of estro-
gens and increased adipose tissue lipolysis.  
The low density lipoprotein cholesterol 
and VLDL increase in parallel to the estrogen. 
HDL-C levels did not change dramatically during 
pregnancy, i.e. HDL-C increases slightly and 
remains high or in some patient goes down, but 
basically normal to delivery [8]. In the study 
that was conducted by Yang et al. [17], a ne-
gative correlation was found between the HDL-
C levels and the neonatal birth weight. In the 
present study we stated that the negative cor-
relation was found between HDL-C and LGA 
newborns (r = -0.17, p < 0.05), but without inde-
pendent influence on LGA, when other lipid 
parameters were added. HDL-C values were in 
the normal range according to NCEP [18] in 
both groups. LDL-C levels were above the nor-
mal range in both diabetic pregnant women, and 
the linear multiple regression analysis revealed 
their predictive value for LGA newborns.  
 Lipids exhibit some adverse effects on 
the mother. Women with preeclampsia have 
high serum lipids in pregnancy. Hyperlipide-
mia might favor production of lipid peroxides 
and alter the balance of the vasoactive com-
pounds leading to endothelial dysfunction i.e. 
vasoconstrictions. GDM patients are at increa-
sed risk for preeclampsia and it is equal to that 
seen in the insulin resistant pregnant women 
with DM2. Our findings are very supportive to 
this notation. The rate of preeclampsia was 
11.5% and 5.2% in DM2 and GDM patients, 
respectively. Patients with DM2 were older and 
obese. Patients with GDM were overweight 
and had worst lipid profiles. The babies born 
by mothers with GDM were heavier in compa-
rison to the babies of the DM2 patients. On the 
other side, not all GDM mothers were treated 
with insulin. Lower birth weight in DM2 than 
in GDM pregnancies might result from better 
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glycemic control throughout the pregnancy and 
insulin therapy starting before or in early 
pregnancy. In spite of that, mild hypertriglyce-
ridemia and hypercholesterolemia were found, 
whereas the HDL-C levels were in the normal 
range according to NCEP [18]. The proportion 
of SGA in DM2 was higher than in GDM, due 
to the higher percentage of preterm delivery in 
DM2. Probably preeclampsia was the main 
reason for preterm delivery. 
 Obesity is a significant risk factor for 
both DM2 and GDM and may be related to the 
fetal size and adverse perinatal outcomes. In 
this study DM2 patients were obese and GDM 
patients were overweight. Almost all studies 
show the effects of obesity on newborn macro-
somia [19, 20]. In this study the BMI was 
statistically significantly correlated with LGA, 
but without an independent effect on LGA. 
This finding can be explained by the lack of 
normal weight pregnant women in the observed 
cohort. Actually it is one limitation of this study.  
 
5. Conclusion 
This study pointed out the usefulness of 
measurement of the serum lipids in pregnancy. 
Triglycerides and LDL-C in the third trimester of 
pregnancy are independent predictors for fetal 
macrosomia in DM2 and GDM pregnancies. Ma-
ternal serum triglycerides and LDL-C levels de-
termined in the maternal blood taken in the third 
trimester of the pregnancy may identify women 
who will give birth to LGA newborns. With pro-
per regulation of the lipid profile we can avoid 
macrosomia in DM2 and GDM pregnancies. 
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Цел: Комплексни метаболни промени во 
липидниот статус настануваат во тек на бре-
меност кај жени со дијабетес. Целта на истражу-
вањето беше да се открие предиктивната вред-
ност на серумските липиди од третиот триместар 
на бременост кај жени со дијабетес тип 2 (DM2) 
и гестациски дијабетес (GDM) за раѓање на ново-
родено големо за гестациската возраст (LGA). 
Материјал и методи: Анализирани беа 
податоци за 43 бремени жени со DM2 и 200 
жени со GDM. Анализите ги вклучуваа след-
ниве параметри: возраст, индекс на телесна маса 
(BMI), липиден статус, HbA1c во првиот, вто-
риот и третиот триместар од бременоста, пре-
еклампспија и телесна тежина на новородено. 
Резултати: DM2 и GDM-групите пока-
жаа статистички значајни разлики во следниве 
параметри: вкупни липиди, триглицериди, вку-
пен холестерол, BMI, возраст, телесна тежина 
на новородено, инциденца на мало за гестациска 
возраст (SGA) и предвремено пораѓање: 9.4 ± 
2.3 vs. 11.0 ± 2.3 mmol/L, 2.4 ± 1.4 vs. 3.4 ± 1.6 
mmol/L, 5.5 ± 1.2 vs. 6.4 ± 1.4 mmol/L, 30.6 ± 5.4 
vs. 26.9 ± 5.2 kg/m2, 34 ± 7.8 vs. 31.5 ± 5.6 years, 
3183 ± 972 vs. 3533 ± 699 g., 20% vs. 7.5%, 27.9 
vs. 14%, соодветно, p < 0.05). Линеарната мул-
типна регресиона анализа покажа дека тригли-
церидите, LDL-C и вкупниот холестерол беа не-
зависни предиктори за LGA (p < 0.05). 
Заклучок: Триглицеридите и LDL-C во 
третиот триместар од бременоста се независни 
предиктори за фетална макросомија во групите 
бремени жени со DM2 и GDM. Одовде, серум-
ските триглицериди на мајката и нивото на 
LDL-C во крвта на мајката во третиот триместар 
од бременоста може да ги откријат жените кои 
раѓаат LGA-новородени. 
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росомија
 
 
